| Previous Close | 368.5 |
| Open | 371 |
| Day High | 373.65 |
| Day Low | 367.3 |
| 52-Week High | 447.15 |
| 52-Week Low | 318.4 |
| Volume | 2.88M |
| Average Volume | 3.1M |
| Market Cap | 599.29B |
| PE | 92.87 |
| EPS | 3.96 |
| Moving Average 50 Days | 366.46 |
| Moving Average 200 Days | 390.49 |
| Change | -0.45 |
Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 12:26 PM GMT
•New oncology assets to include proposed biosimilars for Trastuzumab/Hyaluronidase combination (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®) and Pembrolizumab (Keytruda®) •Company to outline integration as a wholly owned subsidiary into Bio
Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States
GlobeNewswire Inc.
Jul 15, 2025 7:25 PM GMT
BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today annou